|
KMID : 0354719720010010049
|
|
Journal of Korean Diabetes Association
1972 Volume.1 No. 1 p.49 ~ p.54
|
|
|
Clinical Studies on Glybenclamide(Daonil), a New Hypoglycemic Sulfonylurea in Korea
|
|
|
|
|
Abstract
|
|
|
The hypoglycemic effect of glybenclamide (Daonil), a new derivates of the hypoglycemic sulfonylureas, was studied on 41 diabetics registered at the Diabetic Clinics of Seoul National University Hospital. Observing the effect after administering for 13 months to these patients, the results were as follows:
1. Glybenclamide was given to 20 cases who had no experience of previous treatment and the result of excellent or good control was obtained in 18 cases (90%).
2. In 14 cases who had been treated with other sulfonylurea derivatives, 10 cases (71.4%) showed excellent or good control.
3. Glybenclamide treatment in 7 cases who had been treated with about 20 units of N.P.H. resulted in excellent or good control of diabetes in 5 cases (71.4%).
4. The influence of age, body weight, duration of disease and complication on the effect of glybenclamide was studied. According to the result, difference of age showed no remarkable influence on the effect of glybenclamide, but relatively better results were obtained in the group of obese patients. The shorter the duration of disease, the better the results. The patient with minor complication had same result as those who had no complications.
5. Glybenclamide, a sulfonylurea derivative with strong hypoglycemic effect, can be said to be one of the strongest oral hypoglycemic agents. Considering absence of any remarkable side effects or ´toxicity during the clinical studies and its relatively low dose necessary for diabetes control, glybenclamide is thought the most effective agent in long term therapy of diabetes.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|